GSK (LSE:GSK) told investors that Japan's Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of Shingrix, its recombinant zoster vaccine, for the prevention of shingles.
The pharmaceutical group's vaccine previously required healthcare professionals to manually combine a dry antigen vial with a liquid adjuvant vial before use, a step the new ready-to-use syringe eliminates.
Approximately 1.1 million people develop shingles in Japan each year, with risk increasing with age and among those with weakened immune systems, according to cited epidemiological research.
Shingrix has been approved in Japan for adults aged 50 and over since 2018, and extended to adults 18 and over at increased risk since 2023.
"Shingles is a disease that 1 in 3 adults globally will develop in their lifetime," said Sanjay Gurunathan, GSK's head of vaccines and infectious diseases research and development, adding that the new presentation makes administration easier for Japan's healthcare community.
The prefilled syringe launched in the US in February and is rolling out across Europe through the rest of the year.
GSK said the Japan approval rests on data showing technical comparability with the existing two-vial presentation, with no change to indication or dosing.
News Intelligence what this means for the company
Japan's health ministry approved a prefilled syringe version of Shingrix, eliminating the need for healthcare workers to manually combine two vials before administration. The approval follows the US launch in February and European rollout, extending GSK's effort to simplify vaccine delivery across major markets; Japan sees approximately 1.1 million shingles cases annually, with Shingrix already approved there since 2018 for adults 50+ and since 2023 for younger adults at increased risk.
The prefilled syringe is a formulation convenience that removes an operational friction point for healthcare providers but carries no change to indication, dosing, or clinical efficacy—a modest incremental improvement to an already-approved vaccine rather than a material expansion of Shingrix's addressable market or clinical profile.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
